CN1617737A - 用于使哺乳动物组织中的脂质水平正常化的组合物和方法 - Google Patents
用于使哺乳动物组织中的脂质水平正常化的组合物和方法 Download PDFInfo
- Publication number
- CN1617737A CN1617737A CNA028275691A CN02827569A CN1617737A CN 1617737 A CN1617737 A CN 1617737A CN A028275691 A CNA028275691 A CN A028275691A CN 02827569 A CN02827569 A CN 02827569A CN 1617737 A CN1617737 A CN 1617737A
- Authority
- CN
- China
- Prior art keywords
- cgrp
- receptor
- lipid
- amylopectin
- affinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33342201P | 2001-11-26 | 2001-11-26 | |
NZ51573101 | 2001-11-26 | ||
NZ515731 | 2001-11-26 | ||
US60/333,422 | 2001-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1617737A true CN1617737A (zh) | 2005-05-18 |
Family
ID=26652295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA028275691A Pending CN1617737A (zh) | 2001-11-26 | 2002-11-26 | 用于使哺乳动物组织中的脂质水平正常化的组合物和方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1461068A4 (fr) |
JP (1) | JP2005523418A (fr) |
CN (1) | CN1617737A (fr) |
AU (2) | AU2002356469A1 (fr) |
CA (1) | CA2471833A1 (fr) |
WO (1) | WO2003045424A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018392A1 (fr) | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine-oxydase: antagonistes et inhibiteurs |
JP4860906B2 (ja) | 2002-03-08 | 2012-01-25 | プロテミックス コーポレイション リミティド | 心疾患および/または関連心不全の予防および/または治療 |
WO2004017956A1 (fr) | 2002-08-20 | 2004-03-04 | Protemix Corporation Limited | Formes posologiques et traitements s'y rapportant |
US7582796B2 (en) | 2004-07-19 | 2009-09-01 | Protemix Corporation Limited | Synthesis of triethylenetetramines |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
AU2012258976B8 (en) | 2011-05-20 | 2017-07-20 | H. Lundbeck A/S | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
BR112013029959A8 (pt) | 2011-05-20 | 2021-09-08 | Alderbio Holdings Llc | Anticorpos anti-cgrp e anti-cgrpr e seu uso para prevenir ou inibir fotofobia ou aversão à luz, composição farmacêutica compreendendo os referidos anticorpos, bem como sequência de ácido nucleico e célula recombinante |
HUE044062T2 (hu) | 2011-05-20 | 2019-09-30 | Alderbio Holdings Llc | Anti-CGRP készítmények és alkalmazásuk |
TWI712419B (zh) * | 2013-07-03 | 2020-12-11 | 美商艾爾德生物製藥股份有限公司 | 使用抗cgrp抗體之葡萄糖代謝的調節 |
SG11202106766SA (en) | 2019-01-08 | 2021-07-29 | H Lundbeck As | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8720115D0 (en) * | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
US5175145A (en) * | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
WO1994021665A1 (fr) * | 1993-03-24 | 1994-09-29 | Amylin Pharmaceuticals, Inc. | Recepteurs clones et methodes de criblage associees |
DE69433747D1 (de) * | 1994-08-16 | 2004-06-03 | Human Genome Sciences Inc | Calcitoninrezeptor |
AU6596096A (en) * | 1996-07-23 | 1998-02-10 | Smithkline Beecham Corporation | Calcitonin gene-related peptide receptor component factor (houdc44) |
CN1055640C (zh) | 1996-11-29 | 2000-08-23 | 沃维汉 | 人降钙素基因相关肽脂质体组合物及其制法 |
DE69943039D1 (de) * | 1998-02-13 | 2011-01-27 | Amylin Pharmaceuticals Inc | Neue verbindungen mit gemischter amylin aktivität |
-
2002
- 2002-11-26 CA CA002471833A patent/CA2471833A1/fr not_active Abandoned
- 2002-11-26 JP JP2003546925A patent/JP2005523418A/ja active Pending
- 2002-11-26 AU AU2002356469A patent/AU2002356469A1/en not_active Withdrawn
- 2002-11-26 EP EP02803945A patent/EP1461068A4/fr not_active Withdrawn
- 2002-11-26 CN CNA028275691A patent/CN1617737A/zh active Pending
- 2002-11-26 WO PCT/NZ2002/000262 patent/WO2003045424A1/fr active Application Filing
-
2009
- 2009-03-26 AU AU2009201147A patent/AU2009201147A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2002356469A1 (en) | 2003-06-10 |
WO2003045424A1 (fr) | 2003-06-05 |
JP2005523418A (ja) | 2005-08-04 |
AU2009201147A1 (en) | 2009-04-23 |
EP1461068A1 (fr) | 2004-09-29 |
EP1461068A4 (fr) | 2006-03-29 |
CA2471833A1 (fr) | 2003-06-05 |
AU2002356469A2 (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1305897C (zh) | 新肽化合物和其制备方法及含有它们的药物组合物 | |
CN1238367C (zh) | 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用 | |
CN1048731C (zh) | 编码细胞因子抑制性抗炎药物结合蛋白质的多核苷酸 | |
CN1789411A (zh) | 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用 | |
CN1916167A (zh) | 过氧化物酶体增殖物激活受体的调节 | |
CN1886423A (zh) | 脂联素的糖基同工型及其用途 | |
CN1960758A (zh) | 关节炎的治疗剂或预防剂 | |
CN1176947C (zh) | 用于治疗骨质疏松症的甲状旁腺激素类似物 | |
CN1636058A (zh) | 新型丙氨酸转氨酶及其应用方法 | |
CN1884521A (zh) | 发现新基因的方法和使用的计算机系统平台以及新基因 | |
CN1617737A (zh) | 用于使哺乳动物组织中的脂质水平正常化的组合物和方法 | |
CN1796558A (zh) | 分离的编码t细胞诱导因子或白介素-21的核酸分子,其编码的蛋白和其应用 | |
CN1541334A (zh) | 心血管安全测定方法 | |
CN1543350A (zh) | 糖半抗原和聚集的蛋白载体的免疫原性结合物 | |
CN1633506A (zh) | 鉴定5-脂氧化酶作为引起动脉硬化症的主要基因 | |
CN1609616A (zh) | 糖尿病的特异性标记 | |
CN1216900C (zh) | 用于调节免疫系统活性和抑制炎症的细胞调节性亲脂肽 | |
CN1307989C (zh) | 植烷酸在制备治疗糖尿病的药物中的用途 | |
CN1878865A (zh) | 无细胞Notch切割分析方法以及药物筛选方法 | |
CN1850269A (zh) | Gpr39基因在哺乳动物中枢神经系统的功能及其应用 | |
CN1211486C (zh) | 编码前神经肽y原突变体,一种信号肽的突变体,的dna分子及其应用 | |
CN1697878A (zh) | 具有cAMP生成活性的新肽 | |
CN1950103A (zh) | 骨疾病的预防或治疗方法 | |
CN1708589A (zh) | Cns中crh应答基因 | |
CN1927888A (zh) | Glp-1及其类似物与人溶菌酶融合的重组蛋白及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |